Settings
BIIB [NASD]
Biogen Idec Inc.
IndexS&P 500 P/E36.82 EPS (ttm)10.57 Insider Own0.10% Shs Outstand236.16M Perf Week8.85%
Market Cap91.90B Forward P/E23.76 EPS next Y16.38 Insider Trans-4.90% Shs Float235.93M Perf Month13.73%
Income2.51B PEG1.63 EPS next Q3.77 Inst Own92.10% Short Float1.23% Perf Quarter23.52%
Sales9.03B P/S10.18 EPS this Y35.60% Inst Trans0.02% Short Ratio1.67 Perf Half Y16.38%
Book/sh44.14 P/B8.82 EPS next Y21.03% ROA19.80% Target Price381.41 Perf Year22.27%
Cash/sh7.88 P/C49.37 EPS next 5Y22.62% ROE26.60% 52W Range272.02 - 366.17 Perf YTD14.64%
Dividend- P/FCF35.10 EPS past 5Y24.10% ROI20.70% 52W High6.28% Beta1.11
Dividend %- Quick Ratio1.90 Sales past 5Y11.10% Gross Margin87.50% 52W Low43.06% ATR13.51
Employees6850 Current Ratio2.30 Sales Q/Q37.40% Oper. Margin37.70% RSI (14)68.74 Volatility3.28% 3.35%
OptionableYes Debt/Eq0.06 EPS Q/Q76.60% Profit Margin27.80% Rel Volume2.29 Prev Close353.25
ShortableYes LT Debt/Eq0.06 EarningsJan 29 AMC Payout0.00% Avg Volume1.74M Price389.16
Recom2.00 SMA2011.16% SMA5015.18% SMA20020.67% Volume3,981,039 Change10.17%
Jan-30-15Reiterated RBC Capital Mkts Outperform $400 → $445
Jan-30-15Reiterated Deutsche Bank Buy $430 → $460
Oct-22-14Upgrade Robert W. Baird Neutral → Outperform $374 → $382
Aug-19-14Resumed Stifel Buy $376
Jul-29-14Reiterated Argus Buy $360 → $385
Jul-24-14Reiterated UBS Neutral $330 → $354
Jul-09-14Reiterated RBC Capital Mkts Outperform $325 → $375
Mar-19-14Reiterated Stifel Buy $360 → $376
Mar-07-14Reiterated Barclays Overweight $325 → $352
Mar-03-14Reiterated Stifel Buy $330 → $360
Jan-30-14Reiterated UBS Neutral $300 → $310
Jan-30-14Reiterated Brean Capital Buy $293 → $377
Jan-30-14Reiterated Argus Buy $310 → $360
Jan-28-14Reiterated Deutsche Bank Buy $340 → $415
Jan-27-14Reiterated Canaccord Genuity Buy $291 → $355
Jan-16-14Reiterated Stifel Buy $296 → $321
Jan-10-14Reiterated Barclays Overweight $285 → $325
Dec-20-13Reiterated RBC Capital Mkts Outperform $275 → $325
Dec-12-13Reiterated Argus Buy $280 → $310
Oct-30-13Initiated FBR Capital Mkt Perform $259
Jan-31-15 08:02AM  Super Bowl Stocks: Seattle's Best Vs. Boston Strong at Investor's Business Daily
Jan-30-15 05:51PM  Friday's Market Recap Yahoo Finance Contributors +10.17%
03:14PM  Is the 'January Effect' Signaling a Down Year for the Stock Market? at TheStreet
01:47PM  Indexes Mired In Red; Amazon, Biogen, Visa Buck Trend at Investor's Business Daily
01:15PM  As Biogen shares hit all-time high, profits and headcount grow, too at American City Business Journals
12:15PM  Upside play in biotech space CNBC
12:01PM  Stocks Extend Losses; Biogen Idec Gains at Investor's Business Daily
11:45AM  Biogen, Intercept post double-digit gains at MarketWatch
11:40AM  Biogen Tops Q4 Earnings, Provides Strong Outlook for 2015 - Analyst Blog Zacks
11:13AM  Biogen Idec (BIIB) Earnings Report: Q4 2014 Conference Call Transcript at TheStreet
10:38AM  Cramer: Shares of Biogen Head Higher; Questions Surround Deckers at TheStreet
10:37AM  Stocks Open Down In Weak Trade; Biogen, Visa Soar On Q4 Results at Investor's Business Daily
10:35AM  Did Biogen Run Too Much After Earnings? 24/7 Wall St.
09:23AM  Cramer's Mad Dash: BIIB & DECK CNBC
09:06AM  Morning Movers: Stocks Slip On GDP News; MasterCard, Visa Biogen Jump at Barrons.com
Jan-29-15 06:49PM  Biogen, Alexion Earnings Top Views, Shares Jump Investor's Business Daily
05:47PM  Biogen Idec to add 100 jobs in RTP at American City Business Journals
05:32PM  Biogen's Profit Nearly Doubles at The Wall Street Journal
05:27PM  Biogen tops 4Q profit forecasts AP
04:33PM  Biogen forecasts 2015 earnings well ahead of Street view Reuters
04:30PM  Biogen shares jump after company reports earnings at MarketWatch
04:30PM  Biogen Idec Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:05PM  BIOGEN IDEC INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:01PM  Biogen Idec 2014 Revenues Increase 40% to $9.7 Billion Business Wire
01:28PM  Alexion Beats Q4 Estimates, Appoints New CEO at Investor's Business Daily
10:23AM  Credit Suisse Previews Biogen, Says 'Consensus Tecfidera Downgrades = Pipeline Buying Opportunity' Benzinga
10:10AM  Vertex Posts Wider 4Q Loss, Affirms Kalydeco Outlook - Analyst Blog Zacks
07:07AM  Q4 2014 Biogen Idec Inc Earnings Release - After Market Close CCBN
04:40AM  Biogen Idec, Fondazione Telethon and Ospedale San Raffaele Announce Global Collaboration to Develop Gene Therapies for Hemophilia Business Wire
Jan-28-15 03:00PM  What to Watch in the Day Ahead - Thursday, Jan. 29 Reuters
08:00AM  NFL Hall of Famer Earl Campbell And Son Tyler Campbell Pair Up With Biogen Idec To Celebrate The Inspiring Stories Of People With Relapsing Multiple Sclerosis PR Newswire
06:05AM  Up to Speed: Peltz receives ammo in fight against DuPont (Video) at American City Business Journals
Jan-27-15 12:00PM  Will Biogen (BIIB) Surpass Q4 Earnings Expectations? - Analyst Blog Zacks
09:00AM  Google, Biogen Seek Reasons for Advance of Multiple Sclerosis at Bloomberg
Jan-26-15 06:42PM  Big Cap Stocks Mylan, American Tower Near Buy Points at Investor's Business Daily
05:51PM  Biogen Idec Earnings: What to Watch at The Wall Street Journal
05:25PM  CORRECTING AND REPLACING Biogen Idec to Report Fourth Quarter and Year End 2014 Financial Results on January 29, 2015 Business Wire
08:02AM  Apple, Facebook Lead This Week's IBD 50 Earnings at Investor's Business Daily
Jan-24-15 08:02AM  Apple, Facebook Lead Top IBD 50 Earnings This Week at Investor's Business Daily
Jan-23-15 07:36PM  Lightning Round: These stocks bottomed last week at CNBC
Jan-22-15 09:00AM  /R E P E A T -- Corporate Knights announces 11th annual Global 100 index/ CNW Group
04:13AM  US investors double down on biotech bets at Financial Times
Jan-21-15 06:30PM  New Highs: Anheuser-Busch, Infosys Break Out at Investor's Business Daily
04:00PM  Corporate Knights announces 11th annual Global 100 index CNW Group
11:02AM  Biotech Stock Roundup: EU Approvals for AbbVie & Celgene Drugs, CytRx Partial Clinical Hold Lifted - Analyst Blog Zacks
06:00AM  [video]'Mad Money' Lightning Round: I Want You to Own Perrigo at TheStreet
Jan-20-15 06:56PM  Lightning Round: I prefer this to Alibaba at CNBC
04:49PM  Tuesday's Market Recap Yahoo Finance Contributors
04:43PM  The 5 Biggest Biotech Stocks Benzinga
01:00PM  With $450M sale, Alnylam has more cash than any pre-commercial biotech at American City Business Journals
12:28PM  Jefferies 'Encouraged' By Biogen Idec's New Data Benzinga
Jan-16-15 04:59PM  Great Humblers: (Jeez! We Shoulda Seen 'Em Coming) at Forbes
11:06AM  Nomura's Takeways From Biogen Idec's Analyst Meeting Benzinga
Jan-15-15 05:00PM  Isis Pharmaceuticals Earns Milestone Payment from Biogen - Analyst Blog Zacks
10:30AM  Healthcare Executives on a Saturday CNBC
01:00AM  Big Pharma faces up to new price pressure from aggressive insurers Reuters
Jan-14-15 09:30AM  Biopharma's challenges in 2015 CNBC
08:02AM  Meet 5 Top Medical Stocks Making Waves This Week at Investor's Business Daily
03:17AM  Are healthcare stocks good for your wealth? at Financial Times
Jan-13-15 12:45PM  Health care's strong 2015 outlook CNBC
10:38AM  Biogen Strengthened R&D, Will Remain `Active' in M&A: CEO at Bloomberg
Jan-12-15 03:16PM  Biogen Idec beefs up pain pipeline CNBC
Jan-11-15 08:00PM  Biogen to buy private U.K. company with chronic pain drug Reuters
08:00PM  Biogen Idec to Expand Neuropathic Pain Portfolio with the Acquisition of Convergence Pharmaceuticals Business Wire
Jan-09-15 02:56PM  'Free the Webcast!' Investor Transparency Gains Momentum at 'JPM15' Healthcare Confab at TheStreet
01:58PM  Regeneron Can Generate 25% Upside for Investors at Barrons.com
08:00AM  Kite Pharma Expands Senior Management Team With Appointment of Claudine Prowse, Ph.D., as SVP, Corporate Communications and Investor Relations GlobeNewswire
08:00AM  Biogen Idec and Columbia University Medical Center to Conduct Collaborative Genetics Research Business Wire
Jan-08-15 01:57PM  Biogen issues early data on potential game-changing MS drug. Investors shrug. at bizjournals.com
01:13PM  Biogen's MS Drug Shows Promise Despite Study Failures at The Wall Street Journal
11:45AM  Biogen Nerve-Repair Drug Yields Mixed Results at Investor's Business Daily
11:18AM  Biogen Idec: No Big Deal? at Barrons.com
10:35AM  Drug Data Dump: Pfizer, Biogen, AbbVie at Forbes
10:23AM  Stock Market Surges; Nasdaq, S&P 500 Retake 50-Day Lines at Investor's Business Daily
09:40AM  Biogen experimental drug shows evidence of optic nerve repair Reuters
09:28AM  Biogen, Constellation gain; Family Dollar, Alexion drop at MarketWatch
08:52AM  Stocks Poised For Early Pop; Global Payments Gains at Investor's Business Daily
08:50AM  Biogen up as closely watched MS drug shows promise at CNBC
08:34AM  Biogen's Nerve Repair Drug Yields Mixed Results in Key Eye Trial at TheStreet
08:20AM  Biogen MS Drug Shows Some Promise in Repairing Eye Nerve Damage at Bloomberg
07:54AM  Biogen says mid-stage optic nerve treatment study succeeds Reuters
07:54AM  Biogen shares pop on phase II data CNBC
07:30AM  Biogen Idec Reports Positive Top-Line Results from Phase 2 Anti-LINGO-1 Trial in People with Acute Optic Neuritis Business Wire
06:15AM  Biogen Idec's Critical Nerve Repair Drug is Poised for Big News -- Soon at TheStreet
Jan-07-15 05:19PM  After-hours buzz: WD-40, Brocade, Zumiez & more at CNBC +5.56%
02:48PM  Stock Indexes Gun For Best Pop In 3 Weeks; Monster Breaks Out at Investor's Business Daily
Jan-06-15 10:00AM  UPDATE: Barclays Capital Initiates Coverage On Biogen On Tecfidera Upside Benzinga
Jan-05-15 06:20PM  Hot Biotech Stocks: Isis, Kite Jump On Big Deals at Investor's Business Daily
01:17PM  Isis Pharma To Develop GI Drugs With J&J at Investor's Business Daily
01:10PM  Caterpillar falls on downgrade due to oil and gas exposure at Financial Times
12:56PM  Midday movers: Exxon Mobil, Chevron, Hess & more at CNBC
11:25AM  Playing Love It-Hate It With Biogen Idec at Barrons.com
05:00AM  Step aside Wall Street, small pharma CEO pay reaches for the sky at Fortune
Jan-02-15 11:59AM  Stocks Reverse Lower; Apple Plunges Below Support at Investor's Business Daily
Dec-31-14 01:36PM  Stocks Surrender Early Gains, But Chip Stocks Outperform at Investor's Business Daily
01:15PM  5 Biotech Stocks With Big News Due In January at Investor's Business Daily
Dec-29-14 05:27PM  Will 2015 Be Different For Big Cap Stocks? at Investor's Business Daily
Dec-25-14 08:59AM  AQR Capital increases position in Biogen Idec Market Realist
Dec-24-14 04:56PM  Top U.S. Stock Mutual Funds Of 2014: How They Did It at Investor's Business Daily
01:01PM  Are There Any Winners Left In The Biotech Space? Benzinga
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. It provides AVONEX to treat relapsing MS; TYSABRI to treat relapsing forms of MS and Crohn's disease; RITUXAN for treating relapsed or refractory, follicular, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM to treat severe plaque psoriasis in adult patients; FAMPYRA, an oral compound for the improvement of walking in adult patients with MS; TECFIDERA for the treatment of MS; and GAZYVA, an injection for intravenous infusion that treats an untreated chronic lymphocytic leukemia. The company's products that completed Phase III clinical trials comprise ELOCTATE and ALPROLIX, an inherited disorder that inhibits blood coagulations; and Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; Neublastin for neuropathic pain; and ANTI-TWAEK for lupus nephritis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; BIIB037 for MS; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial products include ISIS-SMNRx for spinal muscular atrophy. Biogen Idec Inc. has collaboration agreements with Genentech, Inc.; Acorda Therapeutics, Inc.; Sangamo BioSciences; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerDec 15Sale346.501,981686,417352Dec 16 04:36 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerDec 04Sale345.88440152,18714,574Dec 05 05:20 PM
Holtzman Steven HEVP Corporate DevelopmentDec 02Sale335.651,749587,0520Dec 03 04:32 PM
Holtzman Steven HEVP Corporate DevelopmentNov 11Sale330.001,750577,5001,749Nov 12 04:24 PM
SCANGOS GEORGE AChief Executive OfficerNov 03Sale320.781,128361,84017,985Nov 04 04:18 PM
SCANGOS GEORGE AChief Executive OfficerOct 01Sale330.971,127373,00319,113Oct 02 04:44 PM
Holtzman Steven HEVP Corporate DevelopmentOct 01Sale330.971,750579,1983,499Oct 02 04:42 PM
SCANGOS GEORGE AChief Executive OfficerSep 02Sale345.471,128389,69020,240Sep 04 04:15 PM
SCANGOS GEORGE AChief Executive OfficerAug 01Sale332.931,128375,54521,368Aug 04 04:43 PM
SCANGOS GEORGE AChief Executive OfficerJul 16Sale312.3712,3163,847,14922,496Jul 18 05:59 PM
SCANGOS GEORGE AChief Executive OfficerJul 15Option Exercise0.0021,339044,874Jul 17 04:45 PM
Posner Brian SDirectorJun 20Sale315.00605190,5756,000Jun 23 04:37 PM
Posner Brian SDirectorJun 13Sale310.50700217,3506,605Jun 16 04:37 PM
SCANGOS GEORGE AChief Executive OfficerJun 02Sale318.93484154,36223,535Jun 03 04:29 PM
Holtzman Steven HEVP Corporate DevelopmentMay 19Sale289.151,221353,0525,749May 20 04:16 PM
COVINO GREGORY FVP, Chief Accounting OfficerMay 01Option Exercise286.7534799,5021,029May 02 04:20 PM
SCANGOS GEORGE AChief Executive OfficerMay 01Sale285.562,123606,24124,019May 02 04:22 PM
Holtzman Steven HEVP Corporate DevelopmentApr 17Sale291.001,221355,3116,970Apr 21 05:07 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerApr 02Option Exercise0.0097502,677Apr 03 04:27 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale308.422,123654,77626,142Apr 02 04:16 PM
Posner Brian SDirectorMar 31Sale296.763,000890,2756,435Apr 01 04:15 PM
DORSA CAROLINEDirectorMar 20Option Exercise53.6410,000536,40024,468Mar 21 04:17 PM
DORSA CAROLINEDirectorMar 20Sale348.8810,0003,488,81314,468Mar 21 04:17 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentMar 19Sale352.293,5051,234,7767,976Mar 21 04:15 PM
Holtzman Steven HEVP Corporate DevelopmentMar 17Sale334.831,221408,8278,191Mar 18 05:08 PM
Kingsley Stuart AEVP, Global Comm. OperationsMar 11Sale336.838,4282,838,7663,511Mar 12 07:15 PM
SCANGOS GEORGE AChief Executive OfficerMar 10Sale333.7726,1248,719,37828,265Mar 12 07:20 PM
LEAMING NANCYDirectorMar 10Sale327.652,000655,3007,660Mar 12 07:16 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 04Sale342.583,1711,086,32115,407Mar 05 03:12 PM
SCANGOS GEORGE AChief Executive OfficerMar 03Sale335.792,942987,89454,389Mar 04 03:19 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 26Sale342.171,048358,59421,407Feb 27 04:19 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 23Option Exercise0.001,988023,395Feb 25 02:21 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 23Option Exercise0.002,598026,706Feb 25 02:17 PM
Clancy Paul JExecutive VP and CFOFeb 23Option Exercise0.004,280017,473Feb 25 02:11 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 23Option Exercise0.003,821023,930Feb 25 02:07 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 18Sale327.901,222400,6949,412Feb 19 04:23 PM
DiPietro KennethEVP Human ResourcesFeb 13Sale316.811,290408,6850Feb 14 04:36 PM
SCANGOS GEORGE AChief Executive OfficerFeb 13Sale316.81486153,97057,331Feb 14 04:37 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 13Sale316.42425134,47821,407Feb 14 04:42 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 12Option Exercise0.002,246012,998Feb 14 04:33 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 12Option Exercise0.003,573013,166Feb 14 04:48 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.002,807014,517Feb 14 04:46 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 12Option Exercise0.002,142021,119Feb 14 04:43 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.0071401,941Feb 14 04:45 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 12Option Exercise0.00792014,459Feb 14 04:42 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 12Option Exercise0.002,142011,644Feb 14 04:39 PM
SCANGOS GEORGE AChief Executive OfficerFeb 12Option Exercise0.009,189062,150Feb 14 04:37 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.002,24602,246Feb 14 04:36 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 12Option Exercise0.003150690Feb 14 04:38 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.002,246025,167Feb 14 04:34 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 11Sale314.312,085655,33613,667Feb 12 05:03 PM
SCANGOS GEORGE AChief Executive OfficerFeb 11Sale314.312,456771,94552,961Feb 12 05:00 PM
SCANGOS GEORGE AChief Executive OfficerFeb 10Option Exercise0.0018,833064,297Feb 11 07:55 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 09Option Exercise0.004,691025,133Feb 11 06:07 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 09Option Exercise0.003,909020,723Feb 11 06:07 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Option Exercise0.001,824016,346Feb 11 07:43 PM
Clancy Paul JExecutive VP and CFOFeb 09Option Exercise0.004,691013,922Feb 11 07:49 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,270050,314Feb 11 07:55 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 09Option Exercise0.001,824011,613Feb 11 07:52 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 08Option Exercise0.002,636011,032Feb 11 07:52 PM
Clancy Paul JExecutive VP and CFOFeb 08Option Exercise0.003,191010,278Feb 11 07:49 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 08Option Exercise0.003,468011,229Feb 11 07:47 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,705010,778Feb 11 07:45 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 08Option Exercise0.001,277014,944Feb 11 07:43 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 08Option Exercise0.002,498017,633Feb 11 06:07 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,023021,883Feb 11 06:07 PM
DiPietro KennethEVP Human ResourcesFeb 04Sale299.011,655494,8620Feb 05 04:36 PM